Christopher Mehlin

Company: Link Immunotherapeutics Inc.

Job title: Chief Scientific Officer

Seminars:

Bispecific & Beyond: Bringing a Bispecific to the Clinic & Adding Valency for Specificity & Co-Stimulation 11:30 am

Examining LNK101, a best-in-class mesothelin x CD3 bispecific Using avidity to drive specificity, avoid soluble sink Leveraging co-stimulation for sustained T cell engagementRead more

day: Pre-Conference Seminar Day - Immune Cell Modulators with Multispecifics Seminar

Panel Discussion: Navigating the Unknown: Strategies for Assessing Bispecific Targets Without a Clear Mechanism of Action 12:00 pm

The development of bispecifics targeting novel or poorly understood targets can be challenging when there is no clear understanding of the underlying mechanism of action. This panel discussion will enable you to hear from experts on: The role of preclinical models in identifying potential targets and assessing their suitability for bispecific antibody development The importance…Read more

day: Conference Day One - Target Discovery AM